Mayo Clinic Study Reveals Treatment Gaps in ME/CFS and Long COVID Care

Event summary

  • Mayo Clinic study published in Annals of Family Medicine identifies treatment options for ME/CFS, closely related to long COVID.
  • Pre-pandemic U.S. prevalence of ME/CFS was 1M–2.5M; post-pandemic incidence is 15x higher.
  • Analysis of 571 ME/CFS patients found underuse of core-symptom medications despite accessibility.
  • 72% of patients used dietary supplements like vitamin D, B12, and fish oil.
  • Study calls for expanded medical education on ME/CFS management.

The big picture

The study highlights a critical gap in ME/CFS treatment, where generalist clinicians often prescribe medications for secondary symptoms rather than core issues like fatigue and brain fog. This discrepancy is particularly relevant as long COVID cases surge, creating an urgent need for scalable, evidence-based care models. The findings underscore the importance of bridging specialist and nonspecialist knowledge to improve outcomes for a growing patient population.

What we're watching

Treatment Standardization
Whether the study's findings will accelerate adoption of evidence-based treatment protocols for ME/CFS and long COVID.
Education Impact
The pace at which medical education programs integrate ME/CFS training for generalist clinicians.
Long COVID Overlap
How insights from ME/CFS treatment may inform long COVID management strategies.